Annual report pursuant to Section 13 and 15(d)

Stockholders' Equity (Details 2)

v3.20.1
Stockholders' Equity (Details 2)
12 Months Ended
Dec. 31, 2019
$ / shares
shares
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Stock Options, Total Outstanding | shares 7,632,358
Stock Options, Number Exercisable | shares 4,542,144
Grant Price From 0.05 To 2.02 [Member]  
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Stock Options, Grant Price, Minimum $ 0.05
Stock Options, Grant Price, Maximum 2.02
Stock Options, Weighted Average Exercise Price $ 0.89
Stock Options, Total Outstanding | shares 3,290,357
Stock Options, Number Exercisable | shares 3,086,190
Stock Options, Weighted Average Remaining Contractual Term 4 years 3 months 26 days
Grant Price From 2.40 To 4.60 [Member]  
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Stock Options, Grant Price, Minimum $ 2.40
Stock Options, Grant Price, Maximum 4.60
Stock Options, Weighted Average Exercise Price $ 2.47
Stock Options, Total Outstanding | shares 3,649,001
Stock Options, Number Exercisable | shares 998,021
Stock Options, Weighted Average Remaining Contractual Term 8 years 7 months 21 days
Grant Price From 5.30 To 8.86 [Member]  
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Stock Options, Grant Price, Minimum $ 5.30
Stock Options, Grant Price, Maximum 8.86
Stock Options, Weighted Average Exercise Price $ 6.62
Stock Options, Total Outstanding | shares 693,000
Stock Options, Number Exercisable | shares 457,933
Stock Options, Weighted Average Remaining Contractual Term 8 years 4 months 9 days